Literature DB >> 20030789

Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods.

Torunn O Apelseth1, Oystein Bruserud, Tore Wentzel-Larsen, Tor Hervig.   

Abstract

BACKGROUND: Clinical effect of platelet (PLT) transfusion is monitored by measures of PLT viability (PLT recovery and survival) and functionality. In this study we evaluate and compare transfusion effect measures in patients with chemotherapy-induced thrombocytopenia due to treatment of acute leukemia. STUDY DESIGN AND METHODS: Forty transfusions (28 conventional gamma-irradiated and 12 pathogen-inactivated photochemical-treated PLT concentrates [PCs]) were investigated. PC quality was analyzed immediately before transfusion. Samples were collected from thrombocytopenic patients at 1 and 24 hours for PLT increments and thromboelastography (TEG) with assessments of bleeding score and intertransfusion interval (ITI). Data were analyzed by Spearman's correlation. Patient and PC variables influencing the effect of transfusion were analyzed by use of a mixed-effects model.
RESULTS: PLT dose, storage time, and pathogen inactivation correlated with PLT recovery but not with PLT survival (including ITI), TEG, or clinical bleeding. Fever was negatively correlated with PLT survival but did not affect PLT recovery. After 1 and 24 hours, strong correlations were observed within measures of PLT viability and between PLT increment and the TEG value maximal amplitude (MA). Negative correlation was observed between late MA increment and clinical bleeding status after transfusion (r = -0.494, p = 0.008). PLT count increments did not correlate to clinical bleeding status.
CONCLUSIONS: PLT dose and quality of PCs are important for optimal immediate transfusion response, whereas duration of transfusion effect is influenced mainly by patient variables. The TEG value MA correlates with PLT count increments and bleeding, thus reflecting both PLT viability and functionality.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20030789     DOI: 10.1111/j.1537-2995.2009.02540.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  9 in total

1.  [Conventional vs pathogen-inactivated platelet concentrates for the treatment of perioperative coagulopathy. A prospective cohort study].

Authors:  C F Weber; D Meininger; C Byhahn; E Seifried; K Zacharowski; E Adam; R Henschler; M M Müller
Journal:  Chirurg       Date:  2011-04       Impact factor: 0.955

2.  Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™

Authors:  Johannes Irsch; Lily Lin
Journal:  Transfus Med Hemother       Date:  2011-01-27       Impact factor: 3.747

3.  Flow cytometry and thromboelastography to assess platelet counts and coagulation in patients with haematological malignancies.

Authors:  Alex Gatt; Fabian Bonello; Raphael Buttigieg; Samuel Debono; Patricia Brincat; Charlie Grima; Peter Gatt; Thomas Lofaro; Stefan Laspina
Journal:  Blood Transfus       Date:  2014-06-05       Impact factor: 3.443

4.  Assessment of the Clinical Performance of Platelet Concentrates Treated by Pathogen Reduction Technology in Santiago de Compostela.

Authors:  M Dolores Vilariño; Azucena Castrillo; Alfredo Campos; Rachel Kilian; Mercedes Villamayor; Marcia Cardoso
Journal:  Transfus Med Hemother       Date:  2016-10-28       Impact factor: 3.747

5.  Hemostatic function and transfusion efficacy of apheresis platelet concentrates treated with gamma irradiation in use for thrombocytopenic patients.

Authors:  Mei Zhu; Wei Xu; Bao-Long Wang; Hong Su
Journal:  Transfus Med Hemother       Date:  2014-05-22       Impact factor: 3.747

6.  Assays of different aspects of haemostasis - what do they measure?

Authors:  Nahreen Tynngård; Tomas L Lindahl; Sofia Ramström
Journal:  Thromb J       Date:  2015-02-05

Review 7.  Could Microparticles Be the Universal Quality Indicator for Platelet Viability and Function?

Authors:  Elisabeth Maurer-Spurej; Kate Chipperfield
Journal:  J Blood Transfus       Date:  2016-12-08

8.  Prevalence, Risk Factors, and Outcomes of Platelet Transfusion Refractoriness in Critically Ill Patients: A Retrospective Cohort Study.

Authors:  Saeed Arabi; Abdullah O Almahayni; Abdulrahman A Alomair; Emad M Masuadi; Moussab Damlaj; Hasan M Al-Dorzi
Journal:  Crit Care Res Pract       Date:  2021-09-23

9.  Factor XII-Deficient Chicken Plasma as a Useful Target for Screening of Pro- and Anticoagulant Animal Venom Toxins.

Authors:  Benedito C Prezoto; Nancy Oguiura
Journal:  Toxins (Basel)       Date:  2020-01-23       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.